FDA Approves New Drug for Metastatic Pancreatic Cancer
The FDA granted expedited approval to daraxonrasib, a first-in-class targeted therapy for metastatic pancreatic cancer. The drug blocks the mutated KRAS protein found in over 90% of pancreatic cancer cases.
